Presently There Are More Than 100 Companies Developing More Than 190 Antibody Drugs in More Than 350 Clinical Trials.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c39785) has announced the addition of Antibodies in Oncology: Drug Pipeline Update 2006 to their offering.

The commercial and therapeutic success of antibodies like Rituxan, Avastin, and Erbitux will force the industry to look into the next generation of therapeutic antibodies, preparing themselves for the second wave in the lucrative field of therapeutic antibodies. Today, there are more than 100 companies developing more than 190 antibody drugs in more than 350 clinical trials targeting around 40 different cancer indications. The number of antibody targets has increased to over 70 described molecular targets in just a few years.

Investigators - Includes more than 95 principal investigators.

Drug name & Synonyms - Lists commercial, generic and code names for drugs. In all more than 300 names.

Developmental stage Contains more than 190 active antibody drugs in development or more than 350 clinical projects for cancer:

--36 projects in Phase III

--104 projects in Phase II

--69 projects in Phase I

--145 projects in Preclinical

Cancer Indications - Antibody drugs in development for over 40 cancer indications

--Breast cancer

--Colorectal cancer

--Hematological cancers

--Lung cancer

--Melanoma

--Prostate cancer

--Etc.

Targets - More than 70 different targets. Examples:

--alpha-foetoprotein

--aspartate beta-hydroxylase

--carbonic anhydrase IX

--CD19 antigen

--CD22 antigen

--CD4 antigen (p55)

--chorionic gonadotropin, beta polypeptide 

--coagulation factor III (thromboplastin, tissue factor)

--cytotoxic T-lymphocyte-associated protein 4

--fms-related tyrosine kinase 4

--gastrin

--heat shock 90kDa protein 1, alpha

--insulin-like growth factor 1 receptor

--integrin, alpha V (vitronectin receptor, alpha polypeptide, antigen CD51)

--interleukin 6 receptor

--parathyroid hormone-like hormone

--prostate stem cell antigen

--telomerase reverse transcriptase

--t-umor necrosis factor receptor superfamily, member 8

--v-erb-b2 erythroblastic leukemia viral oncogene homologue 2, neuro/glioblastoma derived oncogene homologue (avian)

--Etc

Description - Progress analysis and review of drug development.

A typical drug profile reports on:

--Drug Name & Synonyms

--Investigator(s)

--Indication(s)

--Developmental Stage(s)

--Mechanism(s)

--Target(s)

--Clinical Development

--Developmental History

--Scientific Data

--Patents

--In/Out-licensing

--Collaborations

--Analysts Comments

How May Drug Pipeline Update Be of Use?

Show investors/board/management that you are right on top of drug development progress in your therapeutic area.

Find competitors, collaborations partners, M&A candidates etc.

Jump start competitive drug intelligence operations.

Excellent starting point for world wide benchmarking.

Compare portfolio and therapy focus with your peers.

Speed up pro-active in-/outlicensing strategy work.

Fast and easy way of tracking drugs using search engines; just one click and you may search World Wide Web and PubMed for any drug with all its synonyms.

Drug Pipeline Update is Delivered to You as a CD-ROM application.

Drug Pipeline Update is fitted into a CD-ROM based application, for your intelligent usage:

Smart CD-ROM application, which makes it easy to use and navigate by

Multiple search and sort functions included

Drug data is linked to search engines like Google and PubMed

Direct links to web pages from inside the application

Found information is easily shared with others over email, file export or in print

For more information visit http://www.researchandmarkets.com/reports/c39785